MTOR and central nervous system cancer: Other potentially actionable mutations we identified were nonsynonymous mutations in PIK3CA and TSC1, also annotated in both COSMIC [56] and OncoKB [45], and shown to be clinically targetable in breast cancer through PI3K inhibition [57,58] and in central nervous system cancers with mTOR inhibition [59], respectively.